These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 39541774)
1. Effective treatment strategies and key factors influencing therapeutic efficacy in advanced SMARCA4-deficient non-small cell lung cancer. Liu H; Hong Q; Zheng S; Zhang M; Cai L Lung Cancer; 2024 Dec; 198():108022. PubMed ID: 39541774 [TBL] [Abstract][Full Text] [Related]
2. Exploration of efficacy of the first-line treatment for advanced non-small cell lung cancer with primary MET-amplification: Retrospective evaluation of 36 cases. Ding K; Liu D; Jin X; Xu Y Int Immunopharmacol; 2024 Dec; 143(Pt 2):113391. PubMed ID: 39427497 [TBL] [Abstract][Full Text] [Related]
3. Recurrence Risk and Its Impact on Current Treatment Strategies in Early and Locally Advanced NSCLC. Tegenbosch C; Vekens K Anticancer Res; 2024 Dec; 44(12):5495-5500. PubMed ID: 39626904 [TBL] [Abstract][Full Text] [Related]
4. Promising efficacy of immune checkpoint inhibitor plus chemotherapy for thoracic SMARCA4-deficient undifferentiated tumor. Lin Y; Yu B; Sun H; Zhang H; Hu Z; Zhang Y; Wu Z; Sun S; Zhao X; Yu H; Wu X; Li Y; Wang J; Wang H J Cancer Res Clin Oncol; 2023 Sep; 149(11):8663-8671. PubMed ID: 37115272 [TBL] [Abstract][Full Text] [Related]
5. Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis. Yang Y; Chen W; Dong L; Duan L; Gao P Clin Transl Oncol; 2024 Oct; 26(10):2488-2502. PubMed ID: 38625495 [TBL] [Abstract][Full Text] [Related]
6. Exploration of efficacy of different therapy regimens for advanced NSCLC patients with KRAS mutation in the first-line treatment. Wang K; Xu M; Wang Y; Xu C; Hao Y; Song Z Clin Transl Oncol; 2024 Oct; 26(10):2479-2487. PubMed ID: 38625494 [TBL] [Abstract][Full Text] [Related]
7. Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs. Marson AG; Burnside G; Appleton R; Smith D; Leach JP; Sills G; Tudur-Smith C; Plumpton CO; Hughes DA; Williamson PR; Baker G; Balabanova S; Taylor C; Brown R; Hindley D; Howell S; Maguire M; Mohanraj R; Smith PE Health Technol Assess; 2021 Dec; 25(75):1-134. PubMed ID: 34931602 [TBL] [Abstract][Full Text] [Related]
8. Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences. Pillay J; Gaudet LA; Saba S; Vandermeer B; Ashiq AR; Wingert A; Hartling L Syst Rev; 2024 Nov; 13(1):289. PubMed ID: 39593159 [TBL] [Abstract][Full Text] [Related]
9. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone. Lee CC; Chen CW; Yen HK; Lin YP; Lai CY; Wang JL; Groot OQ; Janssen SJ; Schwab JH; Hsu FM; Lin WH Clin Orthop Relat Res; 2024 Dec; 482(12):2193-2208. PubMed ID: 39051924 [TBL] [Abstract][Full Text] [Related]
10. Real-world comparison of the efficacy and safety of atezolizumab versus durvalumab in extensive-stage small cell lung cancer. Vince M; Naqvi SMH; Pellini B; Verbosky M; Melzer D Lung Cancer; 2024 Dec; 198():107999. PubMed ID: 39500124 [TBL] [Abstract][Full Text] [Related]
12. Real-world overview of therapeutic strategies and prognosis of older patients with advanced or metastatic non-small cell lung cancer from the ESME database. Cabart M; Mourey L; Pasquier D; Schneider S; Léna H; Girard N; Chouaid C; Schott R; Hiret S; Debieuvre D; Quantin X; Madroszyk A; Dubray-Longeras P; Pichon E; Baranzelli A; Justeau G; Pérol M; Bosquet L; Cabarrou B J Geriatr Oncol; 2024 Sep; 15(7):101819. PubMed ID: 39068144 [TBL] [Abstract][Full Text] [Related]
13. [Relationship between ripretinib concentration and the prognosis of advanced gastrointestinal stromal tumors in China: a multicenter study]. Xu H; Sun XF; Qian HR; Wang M; Wu X; Zhou Y; Wang F; Sun LN; Wang YQ; Li FY; Zhang Q; Xu ZK Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Nov; 27(11):1133-1140. PubMed ID: 39572178 [No Abstract] [Full Text] [Related]
14. Stereotactic vs Hypofractionated Radiotherapy for Inoperable Stage I Non-Small Cell Lung Cancer: The LUSTRE Phase 3 Randomized Clinical Trial. Swaminath A; Parpia S; Wierzbicki M; Kundapur V; Faria S; Okawara GS; Tsakiridis TK; Ahmed N; Bujold A; Hirmiz K; Owen T; Leong N; Ramchandar K; Filion E; Lau H; Gabos Z; Thompson R; Yaremko B; Mehiri S; Louie AV; Quan K; Levine MN; Wright JR; Whelan TJ JAMA Oncol; 2024 Nov; 10(11):1571-1575. PubMed ID: 39298144 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety analysis of immunotherapy in non-small cell lung cancer patients with MET alterations. Wang Y; Wei J; Xu M; Xiang J; Shao K; Hao Y; Song Z Clin Transl Oncol; 2024 Oct; 26(10):2503-2512. PubMed ID: 38627317 [TBL] [Abstract][Full Text] [Related]
16. Mutant-allele dispersion correlates with prognosis risk in patients with advanced non-small cell lung cancer. Wang CX; Yan J; Lin S; Ding Y; Qin YR J Cancer Res Clin Oncol; 2023 Sep; 149(11):8545-8555. PubMed ID: 37093348 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of a Therapy Combining Sintilimab and Chemotherapy With Cryoablation in the First-Line Treatment of Advanced Nonsquamous Non-Small Cell Lung Cancer: Protocol for a Phase II, Pilot, Single-Arm, Single-Center Study. Gao Z; Teng J; Qiao R; Qian J; Pan F; Ma M; Lu J; Zhang B; Chu T; Zhong H JMIR Res Protoc; 2024 Nov; 13():e64950. PubMed ID: 39514267 [TBL] [Abstract][Full Text] [Related]
18. Prognostic Impact of Bone Metastasis in Patients With Metastatic Urothelial Carcinoma Treated With Durvalumab With or Without Tremelimumab in the DANUBE Study. Stecca C; Abdeljalil O; Sridhar SS Clin Genitourin Cancer; 2024 Dec; 22(6):102215. PubMed ID: 39353213 [TBL] [Abstract][Full Text] [Related]
20. Hepatic artery infusion chemotherapy combined with camrelizumab plus rivoceranib for hepatocellular carcinoma with portal vein tumor thrombosis: a multicenter propensity score-matching analysis. Li Y; Guo J; Liu W; Pang H; Song Y; Wu S; Zhang F; Yan D; Chen J; An C; Li C Hepatol Int; 2024 Aug; 18(4):1286-1298. PubMed ID: 38717693 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]